Modeling severe uncontrolled asthma: Transitioning away from health states
Patients with moderate-to-severe type 2 asthma and a history of exacerbations suffer from frequent exacerbations and reduced lung function and life expectancy. Capturing multiple conditions to simulate long-term outcomes in patients with asthma may provide more realistic projections of exacerbation rates.
Authors
- Siddhesh Kamat (ORCID: https://orcid.org/0000-0001-5205-9184)
- Florence Joulain
- Irina Proskorovsky
- Conrado Franco‐Villalobos
- Andreas Kuznik (ORCID: https://orcid.org/0000-0002-8634-8360)
- Ivan Houisse
- Tereza Lanitis
- Asif Khan (ORCID: https://orcid.org/0000-0001-9158-0116)
Institutions
- Cyprus University of Technology (CY)
- Regeneron (United States) (US)
- SNC-Lavalin (Canada) (CA)
- Sanofi (France) (FR)
- Egis Pharmaceuticals (Hungary) (HU)
Publication Details
- Journal
- Contemporary Clinical Trials Communications
- Published
- 2024-11-07
- DOI
- https://doi.org/10.1016/j.conctc.2024.101390
- Primary Topic
- Asthma and respiratory diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Sanofi
- Regeneron Pharmaceuticals